943592
Last Update Posted: 2014-02-27
Recruiting has ended
All Genders accepted | 18 Years-75 Years |
82 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.
Eligibility
Relevant conditions:
Advanced Hematologic Malignancies
Leukemia
Preleukemia
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov